Title: Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old

Authors: Lavonas EJ, Severtson G, Murrelle EL, Ruby J, Bucher-Bartelson B, Dart RC.

Meeting: American Academy of Addiction Psychiatry (AAAP) Annual Meeting

Date: December 2012

Location: Aventura, FL

Abstract:

**Background:** Unintentional exposures to potent opioid medications by young children can cause severe illness or death. An oral film formulation of buprenorphine/naloxone was introduced in September 2010. The RADARS® System Poison Center program collects data about exposure to opioid medications, including patient age, reason for exposure, specific formulation, and medical outcome; in 2011Q4, 48/57 US poison centers provided data. We sought to determine unintentional exposure rates and associated medical outcomes for buprenorphine/naloxone tablets and oral film among children less than 6 years old.

**Methods:** RADARS System Poison Center program case counts and medical outcomes for unintentional exposures to buprenorphine/naloxone tablets and oral film among children aged 0 – 5 years from October 1, 2010 – December 31, 2011 were analyzed. To account for drug availability in the community, rates were standardized using unique recipients of a dispensed drug (URDD) per year-quarter. Negative binomial regression was used to estimate rates and confidence intervals.

**Results:** Exposures to buprenorphine/naloxone tablets (average 0.68 cases/1,000 URDD; 95% CI: 0.64 – 0.73) were more common than exposures to oral film (average 0.08 cases/1,000 URDD; 95% CI: 0.07 – 0.10; rate ratio 8.1; 95% CI: 6.5 – 10.0; p < 0.0001). Major medical outcomes or death were reported in 0/92 (0%) oral film exposures and 19/869 (2.2%) tablet exposures (p=0.24).

**Conclusions:** Among children aged 0 – 5 years, unintentional exposures to buprenorphine/naloxone oral film are less frequent than exposures to buprenorphine/naloxone tablets after adjustment for drug availability. Major medical outcomes and death were uncommon with either formulation.

**Source of Funding:** Reckitt Benckiser